Featured Publications
Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer
Shan N, Wahler J, Lee H, Bak M, Gupta S, Maehr H, Suh N. Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer. The Journal Of Steroid Biochemistry And Molecular Biology 2016, 173: 122-129. PMID: 27923595, PMCID: PMC5459680, DOI: 10.1016/j.jsbmb.2016.12.001.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerVitamin D compoundsCancer stem-like cellsNegative breast cancerBreast cancerStem-like cellsVitamin DCancer stem cellsD compoundsGemini vitamin D analog BXL0124Early breast cancer preventionBreast cancer stem-like cellsBreast cancer stem cell maintenanceBasal-like breast cancerMammosphere cultureBreast cancer preventionCancer cellsCancer stem cell markersPotential preventive agentBreast cancer subtypesBreast cancer cell linesTriple-negative breast cancer cell linesSmooth muscle actinBreast cancer cellsStem-like propertiesKPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells
Cordover E, Wei J, Patel C, Shan N, Gionco J, Sargsyan D, Wu R, Cai L, Kong A, Jacinto E, Minden A. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells. Chemical Research In Toxicology 2019, 33: 482-491. PMID: 31876149, PMCID: PMC9316853, DOI: 10.1021/acs.chemrestox.9b00376.Peer-Reviewed Original ResearchConceptsCell growthSerine/threonine kinase mTORNicotinamide phosphoribosyltransferaseBreast cancer cellsTNBC cellsRegulation of RictorPak4 protein kinaseCancer cellsInhibition of PAK4Triple-negative breast cancerTriple-negative breast cancer cellsMTORC2 signalingKinase mTORProtein kinaseRNA sequencingTNBC cell growthNegative breast cancer cellsCell metabolismRictorPAK4Overexpressing cellsSpecific inhibitorDruggable targetsMTOR pathwayInhibits growth
2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitro